Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares of the company’s stock, valued at $36,324,409.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00.
• On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00.
• On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total transaction of $293,949.00.

Natera Stock Performance

Shares of Natera stock traded up $0.65 during trading on Friday, hitting $127.78. 2,190,370 shares of the stock were exchanged, compared to its average volume of 1,369,813. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a fifty day moving average price of $114.45 and a 200-day moving average price of $105.31. The stock has a market capitalization of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s quarterly revenue was up 58.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.97) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of research reports. Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and set a $150.00 price objective on shares of Natera in a report on Friday, September 13th. BTIG Research boosted their target price on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. UBS Group decreased their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $120.07.

Institutional Investors Weigh In On Natera

Several hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new stake in Natera during the second quarter worth approximately $28,000. Principal Securities Inc. bought a new position in shares of Natera during the fourth quarter worth approximately $32,000. Quarry LP lifted its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its stake in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. Finally, YHB Investment Advisors Inc. acquired a new position in Natera in the 1st quarter valued at $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.